吉西他滨联合顺铂和长春瑞滨联合顺铂方案治疗晚期非小细胞肺癌疗效及不良反应比较  

Side effects of gemcitabine plus cisplation therapy and navelbine plus cisplation therapy for non-small cell lung cancer

作　　者：刘姝梅[1] 杨海涛[1] 季淑玉[1] 郭式敦[1] 

机构地区：[1]山东省聊城市人民医院呼吸内科,252000

出　　处：《中国医药》2009年第2期103-104,共2页China Medicine

摘　　要：目的评价吉西他滨联合顺铂（GP方案）与长春瑞滨联合顺铂（NP方案）治疗晚期非小细胞肺癌（NSCLC）的疗效和不良反应。方法85例晚期NSCLC患者采用完全随机法分为GP组42例和NP组43例。分别用GP方案和NP方案化疗2个周期后对2组的临床疗效和不良反应进行评价。结果GP组有效率为40．5％，NP组为39．5％，2组间比较差异无统计学意义（P〉0．05）。2组不良反应主要为骨髓抑制，GP组血小板减少高于NP组（P〈0．05），NP组白细胞下降高于GP组（P〈0．05），均可耐受。结论吉西他滨或长春瑞滨联合顺铂治疗晚期NSCLC具有较好的耐受性和临床疗效，不良反应有所不同，但都可以耐受。Objective To evaluate side effects of gemcitabine plus cisplation （GP Programme） therapy and navelbine plus cisplation （NP programme） therapy for non-small cell lung cancer （NSCLC）. Methods Eightfive advanced non-small cell lung cancer patients were divided into 2 groups ： 42 with GP and 43 with NP. Results The response rates of GP and NP group were 40.5% and 39.5% respectively. There was no significant difference in response rate between the two groups （P 〉 0. 05 ）. The major adverse reactions were myelosuppression. Thrombocytopenia in GP Group was higher than NP group. leukopenia in NP Group was higher than GP group. Conclusion Both GP and NP regimens are effective for advanced NSCLC. The side effects of the two regimens are different but all adverse reactions are tolerable.

关 键 词：非小细胞肺癌 吉西他滨 长春瑞滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]